Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The Pharma Letter16h
New duvakitug data reinforce best-in-class potential
French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...
Hosted on MSN9h
Hiking Arches National Park in the Summer: A Complete Guide
Each year, hundreds of thousands of people visit Arches National Park to go hiking in the summer months, hoping for long, ...
Santé log10h
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
About duvakitug Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 ...
Walmart's worst week since 2022: Retailer's former U.S. CEO Bill Simon thinks Wall Street is getting earnings, tariff risks wrong
Walmart shares just saw their worst weekly performance since May 2022 — tumbling almost 9%. The stock price fell more than 6% ...